. 2017 Jun 5;9(3):256–262. doi: 10.5114/jcb.2017.68215

Table 2.

Univariate analysis (5-year results)

Parameter	Nr Pts	Local control	p	Metastases-free survival	p	Disease-free survival	p	Overall survival	p
Group
Primary	44	90.9	0.015	63.4	0.123	60.2	0.848	95.2	0.342
Recurrent	63	74.2	0.015	74.2	0.123	57.6	0.848	82.6	0.342
Histology
UPS	27	95.8	0.125	62.4	0.284	62.4	0.895	82.9	0.069
Synovial sarcoma	20	85.0		67.8		58.3		82.1
Myxofibrosarcoma	13	68.4		83.9		60.6		100.0
Liposarcoma	19	71.9		81.2		53.8		100.0
Leiomyosarcoma	11	90.9		63.6		63.6		72.7
Other	17	68.4		64.9		55.4		90.9
Margins
Wide	72	86.1	0.075	73.6	0.626	63.3	0.369	91.6	0.259
Marginal	29	70.5		61.0		48.2		77.9
Intralesional	6	66.7		67.7		50.0		83.3
Gender
Male	56	83.0	0.392	71.3	0.755	59.3	0.864	86.7	0.858
Female	51	78.5	0.392	68.4	0.755	58.0	0.864	88.2	0.858
Age
≤ 54	54	79.5	0.700	68.1	0.814	56.2	0.800	91.2	0.196
> 54	53	82.7	0.700	72.3	0.814	62.0	0.800	82.8	0.196
Site
Upper limb	34	64.7	0.027	61.5	0.370	38.4	0.034	77.9	0.422
Lower limb	64	90.1		75.8		71.0		89.8
Trunk	9	74.1		55.6		41.7		100.0
Grade
2	10	67.5	0.203	88.9	0.202	56.3	0.980	83.3	0.794
3	97	82.2	0.203	67.9	0.202	58.7	0.980	87.6	0.794
pT
T1b	48	76.9	0.420	75.8	0.115	62.2	0.283	81.6	0.195
T2b	59	84.3	0.420	65.3	0.115	56.0	0.283	92.4	0.195
Stage
II	49	75.3	0.196	76.2	0.092	60.9	0.421	81.7	0.201
III	58	85.8	0.196	64.8	0.092	57.0	0.421	92.3	0.201
CT Pre
No	89	81.5	0.361	69.7	0.960	58.2	0.656	88.6	0.245
Yes	18	76.9	0.361	70.5	0.960	60.6	0.656	81.0	0.245
CT Post
No	82	78.8	0.389	74.3	0.147	60.7	0.575	89.4	0.244
Yes	25	87.8	0.389	54.9	0.147	52.1	0.575	81.3	0.244

CT – chemotherapy, UPS – undifferentiated pleomorphic sarcoma